Fc domain effector activity in dengue disease
Fc domain effector activity in dengue disease
批准号:
10595526
负责人:
JEFFREY Victor RAVETCH
金额:
$58.61万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-04-01 至 2024-03-31
关键词:
AffinityAntibodiesAntibody-Dependent EnhancementAntigenic SpecificityAreaBlood PlateletsBlood VesselsCell LineCessation of lifeCharacteristicsClinicalComplexDengueDengue FeverDengue Hemorrhagic FeverDengue InfectionDiseaseDisease susceptibilityEngineeringExhibitsExtravasationFamilyFc domainFeverFlavivirusFlavivirus InfectionsHemorrhagic ShockHumanHuman ActivitiesIgG1ImmuneImmune responseImmunityImmunoglobulin GIn VitroIndividualInfectionInflammatoryInfluenza vaccinationLeukocytesLifeMediatingModelingMonoclonal AntibodiesMorbidity - disease ratePathogenesisPathogenicityPathologyPathway interactionsPatientsPolysaccharidesPopulationPredispositionPrimary InfectionPublic HealthRecording of previous eventsRisk FactorsRoleSeroprevalencesSeveritiesSeverity of illnessShockStructureSymptomsSyndromeTestingThrombocytopeniaVaccinesVariantVirusWest NileYellow FeverZIKAclinical phenotypecohortcross reactivityepidemiologic dataepidemiology studyfollow-uphigh riskhumanized mouseimmunoregulationin vivoinsightmouse modelnovelpreventreceptorresponsesevere denguesocioeconomicsuptakevaccine response
中文摘要
点击翻译按钮获取中文摘要
英文摘要
ABSTRACT – Project 1, Ravetch
Flaviviruses, such as dengue, Zika, and West Nile have a significant impact on public health with tremendous
socioeconomic consequences for a large fraction of the world's population. A feature common to all flaviviruses
is the clear distinction between infection and disease. For example, only a small fraction of dengue-infected
individuals develops dengue disease, which is characterized by a diverse spectrum of clinical symptoms of
variable severity. A large body of epidemiological data suggests that prior flavivirus infection represents the major
risk factor for dengue disease susceptibility. Indeed, susceptibility to severe dengue disease is associated with
the titers of cross-reactive, non-neutralizing IgG antibodies that are elicited during primary infection with other
flaviviruses. The established mechanistic model by which IgG antibodies contribute to disease susceptibility is
based upon the in vitro observation that these antibodies mediate infection of leukocytes through increased
uptake of virus-IgG complexes via specific interactions of their Fc domains with Fcγ receptors (FcγRs); a
phenomenon termed antibody-dependent enhancement (ADE) of infection. Although this model can sufficiently
explain susceptibility to dengue disease, it is likely that complex host susceptibility factors exist that contribute
to disease pathogenesis and determine severity among symptomatic dengue patients. Consistent with this
hypothesis, our recent analysis of the Fc domain structure of IgG antibodies derived from dengue patients with
variable disease severity revealed that specific Fc domain characteristics that confer increased affinity for pro-
inflammatory, activating FcγRs, are enriched in patients with severe disease and evidence for specific clinical
manifestations, including thrombocytopenia and vascular leakage. These antibodies exacerbate disease severity
by inducing platelet depletion via FcγR-mediated mechanisms, suggesting that previously-uncharacterized ADE
mechanisms contribute to disease pathology. Understanding the mechanisms that mediate dengue ADE is
essential for predicting the susceptibility to severe dengue disease in high-risk patient groups and developing
approaches to prevent or reduce disease-associated clinical manifestations. In the proposed studies, we will
analyze the IgG responses from cohorts of dengue-infected patients with variable disease severity to identify the
specific IgG features that are associated with dengue disease severity and clinical manifestations. Follow-up
mechanistic studies in mouse models of dengue disease using strains fully humanized for all classes of FcγRs
will be performed to determine the role of specific human FcγRs in dengue disease and characterize the precise
FcγR pathways that contribute to disease pathogenesis. Lastly, we will characterize IgG responses elicited upon
influenza vaccination of individuals with differential susceptibility to severe flavivirus infection to determine
whether changes in the Fc domain structure represent immune determinants for predicting disease susceptibility.
Our studies will provide novel insights into the mechanisms by which pathogenic IgG antibodies mediate dengue
disease and have a broader impact on our understanding of the pathogenesis of other flaviviruses, like Zika.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Project-003
-
批准号:10170029
-
项目类别:
-
资助金额:$62.61万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10265794
-
项目类别:
-
资助金额:$150.0万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Project-002
-
批准号:10169069
-
项目类别:
-
资助金额:$87.39万
-
财政年份:2020
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10368931
-
项目类别:
-
资助金额:$99.67万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10684073
-
项目类别:
-
资助金额:$44.75万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:8940844
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:10518790
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Molecular mechanisms of antibody-mediated immunotherapies
-
批准号:9888968
-
项目类别:
-
资助金额:$101.7万
-
财政年份:2016
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Enhanced Efficacy of MUC16 directed antibodies through modification of the Fc domain
-
批准号:8933343
-
项目类别:
-
资助金额:$31.55万
-
财政年份:2015
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Administrative Core
-
批准号:10595523
-
项目类别:
-
资助金额:$21.12万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10595522
-
项目类别:
-
资助金额:$208.74万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:10386775
-
项目类别:
-
资助金额:$208.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Administrative Core
-
批准号:10386776
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:9884701
-
项目类别:
-
资助金额:$208.79万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:8827238
-
项目类别:
-
资助金额:$243.34万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:8707655
-
项目类别:
-
资助金额:$243.54万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Fc domain effector activity in dengue disease
-
批准号:10386779
-
项目类别:
-
资助金额:$41.75万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
Integrating innate and adaptive pathways in vaccine responses
-
批准号:9035353
-
项目类别:
-
资助金额:$243.34万
-
财政年份:2014
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
FcR Deficient Mice Susceptibility to Pathogens
-
批准号:8261151
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2011
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
FcR Deficient Mice Susceptibility to Pathogens
-
批准号:8296620
-
项目类别:
-
资助金额:$41.95万
-
财政年份:2011
-
负责人:JEFFREY Victor RAVETCH
-
依托单位:
海外基金